Early and late responders did not differ in respect to sex, age at diagnosis, impaired glucose metabolism (diabetes, impaired fasting glucose or glucose tolerance), GH and IGF1 levels at diagnosis or before pasireotide treatment and tumour volume at diagnosis. This evidence concerns the gene GH1 and neoplasm.